Cargando…

Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)

Introduction Although seborrheic dermatitis (SD) is not lethal, it has a significant impact on the quality of life. Many cases of SD are managed with ketoconazole, but luliconazole has shown an equivalent or lower minimum inhibitory concentration (MIC), but not many studies have been done for its ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Parasramani, Srichand G, Vishwanath, Vishalakshi, Ghia, Deepti, Gandhi, Miti R, Dhoot, Dhiraj, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801137/
https://www.ncbi.nlm.nih.gov/pubmed/36600812
http://dx.doi.org/10.7759/cureus.32035
_version_ 1784861436128788480
author Parasramani, Srichand G
Vishwanath, Vishalakshi
Ghia, Deepti
Gandhi, Miti R
Dhoot, Dhiraj
Barkate, Hanmant
author_facet Parasramani, Srichand G
Vishwanath, Vishalakshi
Ghia, Deepti
Gandhi, Miti R
Dhoot, Dhiraj
Barkate, Hanmant
author_sort Parasramani, Srichand G
collection PubMed
description Introduction Although seborrheic dermatitis (SD) is not lethal, it has a significant impact on the quality of life. Many cases of SD are managed with ketoconazole, but luliconazole has shown an equivalent or lower minimum inhibitory concentration (MIC), but not many studies have been done for its efficacy and safety in SD. With this in mind, we set out to conduct a study comparing the effectiveness, safety, and tolerability of Lulican™ (luliconazole 1% + salicylic acid 3% + ZPTO 1%) shampoo and Ketoconazole (Ketoconazole 2% + ZPTO 1%) shampoo in the treatment of SD. Materials and methods In this prospective, randomized, multi-center study, mild to moderate scalp SD patients were prescribed Lulican™ or Ketoconazole shampoo three times a week for a duration of four weeks. Effectiveness assessment was done with the Seborrheic-Dermatitis-Severity-Score (SDSS) and Physician-Global-Assessment (PGA), and quality of life was assessed with the help of the Scalpdex-23 questionnaire. Results At four weeks, 68% and 57.9% reduction was seen in SDSS in Lulican™ and Ketoconazole shampoo, respectively. Moreover, 58% and 44% of patients achieved excellent to moderate responses as per PGA with Lulican™ and ketoconazole shampoo, respectively. For safety, no statistical difference was reported, but product tolerability and subjective cosmetic acceptability were significantly better in the Lulican™ group as compared to the Ketoconazole group at the end of four weeks. The mean Scalpdex-23 score at week four was reduced by 35.7% and 21.1% in Lulican™ and ketoconazole groups, respectively (p<0.05). Conclusion While both treatments were successful in alleviating SD symptoms and were well tolerated, Lulican™ stood out as a preferred treatment option due to better quality of life (QoL) improvement in SD.
format Online
Article
Text
id pubmed-9801137
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-98011372023-01-03 Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study) Parasramani, Srichand G Vishwanath, Vishalakshi Ghia, Deepti Gandhi, Miti R Dhoot, Dhiraj Barkate, Hanmant Cureus Dermatology Introduction Although seborrheic dermatitis (SD) is not lethal, it has a significant impact on the quality of life. Many cases of SD are managed with ketoconazole, but luliconazole has shown an equivalent or lower minimum inhibitory concentration (MIC), but not many studies have been done for its efficacy and safety in SD. With this in mind, we set out to conduct a study comparing the effectiveness, safety, and tolerability of Lulican™ (luliconazole 1% + salicylic acid 3% + ZPTO 1%) shampoo and Ketoconazole (Ketoconazole 2% + ZPTO 1%) shampoo in the treatment of SD. Materials and methods In this prospective, randomized, multi-center study, mild to moderate scalp SD patients were prescribed Lulican™ or Ketoconazole shampoo three times a week for a duration of four weeks. Effectiveness assessment was done with the Seborrheic-Dermatitis-Severity-Score (SDSS) and Physician-Global-Assessment (PGA), and quality of life was assessed with the help of the Scalpdex-23 questionnaire. Results At four weeks, 68% and 57.9% reduction was seen in SDSS in Lulican™ and Ketoconazole shampoo, respectively. Moreover, 58% and 44% of patients achieved excellent to moderate responses as per PGA with Lulican™ and ketoconazole shampoo, respectively. For safety, no statistical difference was reported, but product tolerability and subjective cosmetic acceptability were significantly better in the Lulican™ group as compared to the Ketoconazole group at the end of four weeks. The mean Scalpdex-23 score at week four was reduced by 35.7% and 21.1% in Lulican™ and ketoconazole groups, respectively (p<0.05). Conclusion While both treatments were successful in alleviating SD symptoms and were well tolerated, Lulican™ stood out as a preferred treatment option due to better quality of life (QoL) improvement in SD. Cureus 2022-11-30 /pmc/articles/PMC9801137/ /pubmed/36600812 http://dx.doi.org/10.7759/cureus.32035 Text en Copyright © 2022, Parasramani et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Parasramani, Srichand G
Vishwanath, Vishalakshi
Ghia, Deepti
Gandhi, Miti R
Dhoot, Dhiraj
Barkate, Hanmant
Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
title Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
title_full Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
title_fullStr Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
title_full_unstemmed Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
title_short Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
title_sort prospective, open-label, multi-centre, randomized study to compare the effectiveness, safety, and tolerability of lulican™ shampoo versus ketoconazole shampoo in indian adult patients with mild to moderate scalp seborrheic dermatitis (lead study)
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801137/
https://www.ncbi.nlm.nih.gov/pubmed/36600812
http://dx.doi.org/10.7759/cureus.32035
work_keys_str_mv AT parasramanisrichandg prospectiveopenlabelmulticentrerandomizedstudytocomparetheeffectivenesssafetyandtolerabilityoflulicanshampooversusketoconazoleshampooinindianadultpatientswithmildtomoderatescalpseborrheicdermatitisleadstudy
AT vishwanathvishalakshi prospectiveopenlabelmulticentrerandomizedstudytocomparetheeffectivenesssafetyandtolerabilityoflulicanshampooversusketoconazoleshampooinindianadultpatientswithmildtomoderatescalpseborrheicdermatitisleadstudy
AT ghiadeepti prospectiveopenlabelmulticentrerandomizedstudytocomparetheeffectivenesssafetyandtolerabilityoflulicanshampooversusketoconazoleshampooinindianadultpatientswithmildtomoderatescalpseborrheicdermatitisleadstudy
AT gandhimitir prospectiveopenlabelmulticentrerandomizedstudytocomparetheeffectivenesssafetyandtolerabilityoflulicanshampooversusketoconazoleshampooinindianadultpatientswithmildtomoderatescalpseborrheicdermatitisleadstudy
AT dhootdhiraj prospectiveopenlabelmulticentrerandomizedstudytocomparetheeffectivenesssafetyandtolerabilityoflulicanshampooversusketoconazoleshampooinindianadultpatientswithmildtomoderatescalpseborrheicdermatitisleadstudy
AT barkatehanmant prospectiveopenlabelmulticentrerandomizedstudytocomparetheeffectivenesssafetyandtolerabilityoflulicanshampooversusketoconazoleshampooinindianadultpatientswithmildtomoderatescalpseborrheicdermatitisleadstudy